EGFR and non-small cell lung carcinoma: Furthermore, the targets in non-small-cell lung cancer pathway were docked with the corresponding compounds and the results showed that 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-(3-methylbut-2-enyl) chromone-4-one and quercetin had good docking ability with AKT1, EGFR, and ALK protein (Figures 1(e)–1(h)).